The effects of enoximone in acute exacerbation COPD: a pilot study

Phase 4

Completed

Conditions: Acute pulmonary attack
Bronchospasm
Exacerbation COPD
10024967

Registration Number: NL-OMON49504

Lead Sponsor: Rijnstate Ziekenhuis

Brief Summary: Trial is onging in other countries

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 4

Inclusion Criteria

Patients with an AE-COPD wherefore intubation occurred within 24 hours before
enrollment.

Exclusion Criteria

Patients with known asthma or interstitial lung disease (ILD)
Known neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS),
Multiple Sclerosis (MS), Guillain-Barre and Dementia
Hypertrophic obstructive cardiomyopathy (HOCM)
Severe aortic stenosis with aortic valve area <1 cm2
Known ventricular arrhythmias
Severe kidney disorders with Glomerular Filtration Rate (GFR) < 30 ml/min
Severe liver insufficiency with spontaneous PT/INR > 1.5
Pregnancy

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Auto-PEEP</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Respiratory parameters:<br /><br>- Lungcompliance in L/cmH2O<br /><br>- Airway resistance in cmH2O/L/s<br /><br>- VCO2<br /><br>- etCO2<br /><br>- FiO2<br /><br><br /><br>Cardiac parameters:<br /><br>- RVSP<br /><br>- Cardiac output<br /><br>- TAPSE<br /><br>- MAPSE<br /><br>- Ejection Fraction of the Left Ventricle<br /><br><br /><br>Arterial blood gas analysis (2 ml of blood, obtained through an arterial<br /><br>cannula):<br /><br>- pH, PaCO2, PaO2, saturation, lactate, base excess,<br /><br><br /><br>Vital Signs:<br /><br>- Occurrence of adverse side effects such as (supraventricular) arrhythmics and<br /><br>hypotension</p><br>